Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ronald Christiaan Elgersma"'
Autor:
Kim Berentsen, Patrick G. Groothuis, Marion Blomenrohr, Ronald Christiaan Elgersma, Wim H. A. Dokter, Danielle Jacobs, Miranda van der Lee, Monique van der Vleuten, Ruud Coumans, Patrick Henry Beusker, Diels van den Dobbelsteen, Ruud Ubink
Publikováno v:
Cancer Research. 81:925-925
5T4 is an oncofetal antigen with low expression in healthy tissues which is frequently overexpressed in different tumor types. Despite its overexpression in various malignancies and its association with poor prognosis, there are currently no marketed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2ba8489a01616ad01a2a8f3a6127680
https://doi.org/10.1158/1538-7445.am2021-925
https://doi.org/10.1158/1538-7445.am2021-925
Autor:
C. Marco Timmers, Tijl Huijbregts, Ronald Christiaan Elgersma, Franciscus M. H. de Groot, GF Verheijden, Ruud Coumans, Patrick Henry Beusker, Jacques M. Lemmens, David F. Egging, Diels van den Dobbelsteen, Miranda M.C. van der Lee, Ruud Ubink, Wim H. A. Dokter, Wiro Michaël Petrus Bernardus Menge, Henri Johannes Spijker, John Joosten
Publikováno v:
Molecular Pharmaceutics. 12:1813-1835
Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug classes: auristatins and maytansinoids. Both are tubulin binders and block the cell in its progression through mitosis. We set
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d112fc7f8b9f7d0584c7c81aa6b00e7
https://doi.org/10.1021/mp500781a
https://doi.org/10.1021/mp500781a
Autor:
Vincent F.M.H. De Groot, Gijs Verheijden, Monique van der Vleuten, Ruud Ubink, Tanja van Achterberg, Eline Loosveld, Wiro Michaël Petrus Bernardus Menge, Henri Johannes Spijker, Tijl Huijbregts, Marco Timmers, Ronald Christiaan Elgersma, Diels van den Dobbelsteen, Wim H. A. Dokter, Michel H.M. Eppink, Ruud Coumans, Danielle Jacobs, Ellen Mattaar, David F. Egging, Miranda van der Lee, John Joosten, Patrick Beusker, Guy de Roo, Patrick Groothuis
Publikováno v:
Molecular Cancer Therapeutics, 13, 2618-2629
Molecular Cancer Therapeutics 13 (2014)
Molecular Cancer Therapeutics 13 (2014)
A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation antibody–drug conjugates (ADC). A leading ADC originating from that platform is SYD983, a HER2-targeting ADC based on tras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6605a6844a687667fb0a9a10c6e87f
https://doi.org/10.1158/1535-7163.mct-14-0040-t
https://doi.org/10.1158/1535-7163.mct-14-0040-t
Autor:
Ruud Coumans, Guy de Roo, David F. Egging, Willem Dokter, Ruud Ubink, Patrick G. Groothuis, Gijs Verheijden, M.H.M. Eppink, Miranda van der Lee, Marco Timmers, Ellen Mattaar, Ronald Christiaan Elgersma, Danielle Jacobs, Patrick Beusker, Monique van der Vleuten, Tanja van Achterberg, Diels van den Dobbelsteen
Publikováno v:
Cancer Research. 74:2651-2651
We have built a linker-drug platform based on a cleavable linker-duocarmycin payload for the development of novel generation antibody-drug conjugates. SYD983, a lead ADC originating from that platform, is a cysteine-coupled HER2-targeting ADC based o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b32fe9cf309c4ff92b9d40d83e71cdf0
https://doi.org/10.1158/1538-7445.am2014-2651
https://doi.org/10.1158/1538-7445.am2014-2651
Autor:
Patrick Beusker, John Joosten, Ruud Coumans, Ronald Christiaan Elgersma, Vincent F.M.H. De Groot, Wiro Michaël Petrus Bernardus Menge, Henri Johannes Spijker
Publikováno v:
Cancer Research. 72:4640-4640
Antibody-Drug Conjugation (ADC) is gaining momentum as a next generation antibody therapeutics approach in oncology. Tumor specific delivery of the cell-killing agent maximizes the agent's potency while avoiding damage to healthy tissue resulting in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::043b97ba794223eb203ea1f4d3c6a6fa
https://doi.org/10.1158/1538-7445.am2012-4640
https://doi.org/10.1158/1538-7445.am2012-4640
Autor:
Patrick Beusker, Vincent F.M.H. De Groot, Ruud Coumans, Ronald Christiaan Elgersma, John Joosten, Wiro Michaël Petrus Bernardus Menge, Henri Johannes Spijker
Publikováno v:
Cancer Research. 70:4397-4397
Antibody-Drug Conjugation (ADC) is gaining momentum as a next generation antibody therapeutics approach in oncology. Tumor specific delivery of the cell-killing agent maximizes the agent's potency while avoiding damage to healthy tissue resulting in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc1538b13a3e167c7a226ba5c987d912
https://doi.org/10.1158/1538-7445.am10-4397
https://doi.org/10.1158/1538-7445.am10-4397